NYSE:EW - Edwards Lifesciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$177.26 -0.23 (-0.13 %)
(As of 04/21/2019 04:00 PM ET)
Previous Close$177.26
Today's Range$172.14 - $180.00
52-Week Range$123.00 - $197.86
Volume2.67 million shs
Average Volume1.15 million shs
Market Capitalization$36.88 billion
P/E Ratio37.71
Dividend YieldN/A
Beta0.91
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; Acumen Hypotension Prediction Index, an advanced algorithm that indicates the likelihood of a patient developing hypotension; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP28176E10
Phone949-250-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.72 billion
Cash Flow$5.1740 per share
Book Value$15.02 per share

Profitability

Net Income$722.20 million

Miscellaneous

Employees12,800
Market Cap$36.88 billion
Next Earnings Date4/23/2019 (Confirmed)
OptionableOptionable

Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Shares of Edwards Lifesciences split before market open on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly issued shares were issued to shareholders after the market closes on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

How will Edwards Lifesciences' stock buyback program work?

Edwards Lifesciences announced that its board has authorized a stock repurchase plan on Thursday, December 7th 2017, which allows the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company's board of directors believes its stock is undervalued.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Corp (NYSE:EW) announced its quarterly earnings data on Thursday, January, 31st. The medical research company reported $1.17 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $1.17. The medical research company earned $977.70 million during the quarter, compared to analyst estimates of $973.72 million. Edwards Lifesciences had a return on equity of 31.09% and a net margin of 19.40%. During the same period in the previous year, the company posted $0.94 EPS. View Edwards Lifesciences' Earnings History.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Tuesday, April 23rd 2019. View Earnings Estimates for Edwards Lifesciences.

How can I listen to Edwards Lifesciences' earnings call?

Edwards Lifesciences will be holding an earnings conference call on Tuesday, April 23rd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8777042848.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences updated its FY19 earnings guidance on Thursday, January, 31st. The company provided earnings per share (EPS) guidance of $5.05-5.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.23. The company issued revenue guidance of $3.9-4.3 billion, compared to the consensus revenue estimate of $4.14 billion.Edwards Lifesciences also updated its Q1 guidance to $1.15-1.25 EPS.

What price target have analysts set for EW?

20 equities research analysts have issued twelve-month price objectives for Edwards Lifesciences' shares. Their forecasts range from $120.00 to $221.00. On average, they expect Edwards Lifesciences' share price to reach $182.15 in the next year. This suggests a possible upside of 2.8% from the stock's current price. View Analyst Price Targets for Edwards Lifesciences.

What is the consensus analysts' recommendation for Edwards Lifesciences?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 6 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Edwards Lifesciences.

What are Wall Street analysts saying about Edwards Lifesciences stock?

Here are some recent quotes from research analysts about Edwards Lifesciences stock:
  • 1. According to Zacks Investment Research, "Edwards Lifesciences exited the third quarter on a mixed note with earnings ahead of the Zacks Consensus Estimate and revenues lagging the same. Strong transcatheter valve sales in the domestic and overseas markets are a major positive. The company also registered strong sales within its Critical Care division banking on which it has raised Critical Care guidance. Further, management is upbeat about CMS opening a National Coverage Analysis to reconsider the National Coverage Determination released in 2012 for transcatheter aortic valve replacement. On the flip side, management expects underlying sales growth in THVT for 2018 to remain at around 12.5% because of limited contribution from Cardioband and a newly-revised rollout strategy for SAPIEN 3 Ultra. Also, tough competition in the cardiac devices market and reimbursement issues continue to raise concern. Overall, in the past three months, Edwards Lifesciences underperformed its industry." (10/25/2018)
  • 2. Northland Securities analysts commented, "We analyze data on MitraClip + GDMT in HFpEF / HFrEF + FMR, & impact on existing clinical trials in both transcatheter mitral repair / replacement programs. There are a ton of unknowns, however, it is likely that: 1) Edwards PASCAL trial will need to be redesigned with MitraClip as the control (even though the trial is in DMR; Medtronic’ APOLLO trial, especially in HFrEF might" not need MitraClip as the comparator). 2) COAPT results are not applicable in real-world setting. Key Points We confess, we don’t have access to raw data in COAPT, hence it is impossible to make definitive arguments." (10/11/2018)

Has Edwards Lifesciences been receiving favorable news coverage?

Media stories about EW stock have been trending neutral on Sunday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Edwards Lifesciences earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days.

Who are some of Edwards Lifesciences' key competitors?

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Visa (V), Home Depot (HD), UnitedHealth Group (UNH), Broadcom (AVGO), salesforce.com (CRM) and Micron Technology (MU).

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the folowing people:
  • Mr. Michael A. Mussallem, Chairman & CEO (Age 66)
  • Mr. Scott B. Ullem, Corp. VP & CFO (Age 52)
  • Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 57)
  • Mr. Robert W. A. Sellers, Principal Accounting Officer, VP & Corp. Controller
  • Dr. Todd J. Brinton, Corp. VP of Advanced Technology & Chief Scientific Officer

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include South Texas Money Management Ltd. (0.17%), Huntington National Bank (0.14%), Calamos Advisors LLC (0.11%), Country Trust Bank (0.09%), Scout Investments Inc. (0.06%) and Nisa Investment Advisors LLC (0.06%). Company insiders that own Edwards Lifesciences stock include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.

Which institutional investors are selling Edwards Lifesciences stock?

EW stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Ledyard National Bank, Eqis Capital Management Inc., Calamos Wealth Management LLC, Gateway Investment Advisers LLC, Chesley Taft & Associates LLC, Cohen Lawrence B and Raymond James Trust N.A.. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.

Which institutional investors are buying Edwards Lifesciences stock?

EW stock was bought by a variety of institutional investors in the last quarter, including Scout Investments Inc., Pacer Advisors Inc., Pennsylvania Trust Co, Pennsylvania Trust Co, Country Trust Bank, Dorsey Wright & Associates, American Research & Management Co. and Oakbrook Investments LLC. View Insider Buying and Selling for Edwards Lifesciences.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $177.26.

How big of a company is Edwards Lifesciences?

Edwards Lifesciences has a market capitalization of $36.88 billion and generates $3.72 billion in revenue each year. The medical research company earns $722.20 million in net income (profit) each year or $4.70 on an earnings per share basis. Edwards Lifesciences employs 12,800 workers across the globe.

What is Edwards Lifesciences' official website?

The official website for Edwards Lifesciences is http://www.edwards.com.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]


MarketBeat Community Rating for Edwards Lifesciences (NYSE EW)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  1,049 (Vote Outperform)
Underperform Votes:  746 (Vote Underperform)
Total Votes:  1,795
MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences and other stocks. Vote "Outperform" if you believe EW will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EW will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/21/2019 by MarketBeat.com Staff

Featured Article: Do Tariffs Work?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel